Antiplatelet agents are the cornerstone of secondary prevention for patients who present with an ischemic stroke or transient ischemic attack (TIA). At present, monotherapy with acetylsalicylic acid (ASA) or clopidogrel or the combination regimen of ASA plus extended-release dipyridamole are recommended as first-line options in the stroke prevention guidelines. The combination of ASA and clopidogrel is not routinely recommended for secondary stroke prevention, since it has been shown to offer no therapeutic advantage and an increased risk of bleeding. The clear answer as to whether one or two antiplatelet agents are better for the secondary prevention of ischemic stroke events in older adults depends upon the combination of agents, as well as the monotherapy comparator.
Key words: stroke prevention, clopidogrel, acetylsalicylic acid, dipyridamole, antiplatelet agents.
Copyright © 2011-2019 Health Plexus Ltd. All rights reserved.